Cargando…

Trimethoprim-sulfamethoxazole induced hyperkalaemia in elderly patients receiving spironolactone: nested case-control study

Objectives To characterise the risk of admission to hospital for hyperkalaemia in elderly patients treated with trimethoprim-sulfamethoxazole in combination with spironolactone. Design Population based nested case-control study. Setting Ontario, Canada, from 1 April 1992 to 1 March 2010. Participant...

Descripción completa

Detalles Bibliográficos
Autores principales: Antoniou, Tony, Gomes, Tara, Mamdani, Muhammad M, Yao, Zhan, Hellings, Chelsea, Garg, Amit X, Weir, Matthew A, Juurlink, David N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group Ltd. 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3171211/
https://www.ncbi.nlm.nih.gov/pubmed/21911446
http://dx.doi.org/10.1136/bmj.d5228
_version_ 1782211727248588800
author Antoniou, Tony
Gomes, Tara
Mamdani, Muhammad M
Yao, Zhan
Hellings, Chelsea
Garg, Amit X
Weir, Matthew A
Juurlink, David N
author_facet Antoniou, Tony
Gomes, Tara
Mamdani, Muhammad M
Yao, Zhan
Hellings, Chelsea
Garg, Amit X
Weir, Matthew A
Juurlink, David N
author_sort Antoniou, Tony
collection PubMed
description Objectives To characterise the risk of admission to hospital for hyperkalaemia in elderly patients treated with trimethoprim-sulfamethoxazole in combination with spironolactone. Design Population based nested case-control study. Setting Ontario, Canada, from 1 April 1992 to 1 March 2010. Participants Cases were residents of Ontario aged 66 years or above receiving chronic treatment with spironolactone and admitted to hospital with hyperkalaemia within 14 days of receiving a prescription for either trimethoprim-sulfamethoxazole, amoxicillin, norfloxacin, or nitrofurantoin. Up to four controls for each case were identified from the same cohort, matched on age, sex, and presence or absence of chronic kidney disease and diabetes, and required to have received one of the study antibiotics within 14 days before the case’s index date. Main outcome measures Odds ratio for association between admission to hospital with hyperkalaemia and receipt of a study antibiotic in the preceding 14 days, adjusted for conditions and drugs that may influence risk of hyperkalaemia. Results During the 18 year study period, 6903 admissions for hyperkalaemia were identified, 306 of which occurred within 14 days of antibiotic use. Of these, 248 (81%) cases were matched to 783 controls. 10.8% (17 859/165 754) of spironolactone users received at least one prescription for trimethoprim-sulfamethoxazole. Compared with amoxicillin, prescription of trimethoprim-sulfamethoxazole was associated with a marked increase in the risk of admission to hospital for hyperkalaemia (adjusted odds ratio 12.4, 95% confidence interval 7.1 to 21.6). The population attributable fraction was 59.7%, suggesting that approximately 60% of all cases of hyperkalaemia in older patients taking spironolactone and treated with an antibiotic for a urinary tract infection could be avoided if trimethoprim-sulfamethoxazole was not prescribed. Treatment with nitrofurantoin was also associated with an increase in the risk of hyperkalaemia (adjusted odds ratio 2.4, 1.3 to 4.6), but no such risk was found with norfloxacin (adjusted odds ratio 1.6, 0.8 to 3.4) Conclusions Among older patients receiving spironolactone, treatment with trimethoprim-sulfamethoxazole was associated with a major increase in the risk of admission to hospital for hyperkalaemia. This drug combination should be avoided when possible.
format Online
Article
Text
id pubmed-3171211
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BMJ Publishing Group Ltd.
record_format MEDLINE/PubMed
spelling pubmed-31712112011-09-23 Trimethoprim-sulfamethoxazole induced hyperkalaemia in elderly patients receiving spironolactone: nested case-control study Antoniou, Tony Gomes, Tara Mamdani, Muhammad M Yao, Zhan Hellings, Chelsea Garg, Amit X Weir, Matthew A Juurlink, David N BMJ Research Objectives To characterise the risk of admission to hospital for hyperkalaemia in elderly patients treated with trimethoprim-sulfamethoxazole in combination with spironolactone. Design Population based nested case-control study. Setting Ontario, Canada, from 1 April 1992 to 1 March 2010. Participants Cases were residents of Ontario aged 66 years or above receiving chronic treatment with spironolactone and admitted to hospital with hyperkalaemia within 14 days of receiving a prescription for either trimethoprim-sulfamethoxazole, amoxicillin, norfloxacin, or nitrofurantoin. Up to four controls for each case were identified from the same cohort, matched on age, sex, and presence or absence of chronic kidney disease and diabetes, and required to have received one of the study antibiotics within 14 days before the case’s index date. Main outcome measures Odds ratio for association between admission to hospital with hyperkalaemia and receipt of a study antibiotic in the preceding 14 days, adjusted for conditions and drugs that may influence risk of hyperkalaemia. Results During the 18 year study period, 6903 admissions for hyperkalaemia were identified, 306 of which occurred within 14 days of antibiotic use. Of these, 248 (81%) cases were matched to 783 controls. 10.8% (17 859/165 754) of spironolactone users received at least one prescription for trimethoprim-sulfamethoxazole. Compared with amoxicillin, prescription of trimethoprim-sulfamethoxazole was associated with a marked increase in the risk of admission to hospital for hyperkalaemia (adjusted odds ratio 12.4, 95% confidence interval 7.1 to 21.6). The population attributable fraction was 59.7%, suggesting that approximately 60% of all cases of hyperkalaemia in older patients taking spironolactone and treated with an antibiotic for a urinary tract infection could be avoided if trimethoprim-sulfamethoxazole was not prescribed. Treatment with nitrofurantoin was also associated with an increase in the risk of hyperkalaemia (adjusted odds ratio 2.4, 1.3 to 4.6), but no such risk was found with norfloxacin (adjusted odds ratio 1.6, 0.8 to 3.4) Conclusions Among older patients receiving spironolactone, treatment with trimethoprim-sulfamethoxazole was associated with a major increase in the risk of admission to hospital for hyperkalaemia. This drug combination should be avoided when possible. BMJ Publishing Group Ltd. 2011-09-12 /pmc/articles/PMC3171211/ /pubmed/21911446 http://dx.doi.org/10.1136/bmj.d5228 Text en © Antoniou et al 2011 This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.
spellingShingle Research
Antoniou, Tony
Gomes, Tara
Mamdani, Muhammad M
Yao, Zhan
Hellings, Chelsea
Garg, Amit X
Weir, Matthew A
Juurlink, David N
Trimethoprim-sulfamethoxazole induced hyperkalaemia in elderly patients receiving spironolactone: nested case-control study
title Trimethoprim-sulfamethoxazole induced hyperkalaemia in elderly patients receiving spironolactone: nested case-control study
title_full Trimethoprim-sulfamethoxazole induced hyperkalaemia in elderly patients receiving spironolactone: nested case-control study
title_fullStr Trimethoprim-sulfamethoxazole induced hyperkalaemia in elderly patients receiving spironolactone: nested case-control study
title_full_unstemmed Trimethoprim-sulfamethoxazole induced hyperkalaemia in elderly patients receiving spironolactone: nested case-control study
title_short Trimethoprim-sulfamethoxazole induced hyperkalaemia in elderly patients receiving spironolactone: nested case-control study
title_sort trimethoprim-sulfamethoxazole induced hyperkalaemia in elderly patients receiving spironolactone: nested case-control study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3171211/
https://www.ncbi.nlm.nih.gov/pubmed/21911446
http://dx.doi.org/10.1136/bmj.d5228
work_keys_str_mv AT antonioutony trimethoprimsulfamethoxazoleinducedhyperkalaemiainelderlypatientsreceivingspironolactonenestedcasecontrolstudy
AT gomestara trimethoprimsulfamethoxazoleinducedhyperkalaemiainelderlypatientsreceivingspironolactonenestedcasecontrolstudy
AT mamdanimuhammadm trimethoprimsulfamethoxazoleinducedhyperkalaemiainelderlypatientsreceivingspironolactonenestedcasecontrolstudy
AT yaozhan trimethoprimsulfamethoxazoleinducedhyperkalaemiainelderlypatientsreceivingspironolactonenestedcasecontrolstudy
AT hellingschelsea trimethoprimsulfamethoxazoleinducedhyperkalaemiainelderlypatientsreceivingspironolactonenestedcasecontrolstudy
AT gargamitx trimethoprimsulfamethoxazoleinducedhyperkalaemiainelderlypatientsreceivingspironolactonenestedcasecontrolstudy
AT weirmatthewa trimethoprimsulfamethoxazoleinducedhyperkalaemiainelderlypatientsreceivingspironolactonenestedcasecontrolstudy
AT juurlinkdavidn trimethoprimsulfamethoxazoleinducedhyperkalaemiainelderlypatientsreceivingspironolactonenestedcasecontrolstudy